Immune reactivity to Trypanosoma cruzi chimeric proteins for Chagas disease diagnosis in immigrants living in a non-endemic setting.

Autor: Dopico E; Laboratori Clínic Territorial Metropolitana Sud, Catalan Institute of Health, Barcelona, Catalonia, Spain., Del-Rei RP; Faculty of Technology and Sciences of Bahia, Salvador, Bahia, Brazil., Espinoza B; Instituto de Investigaciones Biomédicas, Departamento de Inmunología, Universidad Nacional Autónoma de México, Ciudad de México, Mexico., Ubillos I; Laboratori Clínic Territorial Metropolitana Sud, Catalan Institute of Health, Barcelona, Catalonia, Spain., Zanchin NIT; Carlos Chagas Institute, Oswaldo Cruz Foundation, Curitiba, Paraná, Brazil., Sulleiro E; Microbiology Department, Vall d'Hebron University Hospital, PROSICS, Barcelona, Catalonia, Spain., Moure Z; Microbiology Department, Vall d'Hebron University Hospital, PROSICS, Barcelona, Catalonia, Spain., Celedon PAF; Molecular Biology Institute of Paraná, Curitiba, Paraná, Brazil., Souza WV; Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil., da Silva ED; Immunobiological Technology Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Gomes YM; Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil., Santos FLN; Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil. fred.santos@bahia.fiocruz.br.
Jazyk: angličtina
Zdroj: BMC infectious diseases [BMC Infect Dis] 2019 Mar 12; Vol. 19 (1), pp. 251. Date of Electronic Publication: 2019 Mar 12.
DOI: 10.1186/s12879-019-3872-z
Abstrakt: Background: Chronic Chagas Disease (CD) diagnosis is based on serological methods employing crude, semipurified or recombinant antigens, which may result in low sensitivity or cross-reactivity. To reduce these restrictions, we developed a strategy involving use of molecules containing repetitive fragments of Trypanosoma cruzi conserved proteins. Diagnostic performance of IBMP-8.1 and IBMP-8.4 chimeric antigens (Molecular Biology Institute of Paraná - IBMP in Portuguese acronym) was assessed to diagnose T. cruzi-infected and non-infected immigrants living in Barcelona (Spain), a non-endemic setting for Chagas disease.
Methods: Reactivity of IBMP-8.1 and IBMP-8.4 was assessed using an in-house automated ELISA with 347 positive and 331 negative individuals to Chagas disease. Antigenic cross-reactivity was measured with sera samples from pregnant women with Toxoplasma gondii (n = 98) and Zika virus (n = 75) antibodies.
Results: The area under the curve values was 1 and 0.99 for the IBMP-8.1 and IBMP-8.4 proteins, respectively, demonstrating excellent diagnostic accuracy. The reactivity index was higher for IBMP-8.1 than IBMP-8.4 in positive samples and no significant difference in reactivity index was observed in negative samples. Sensitivity ranged from 99.4% for IBMP-8.1 to 99.1% for IBMP-8.4 and was not statistically different. Specificity for IBMP-8.1 reached 100 and 99.7% for IBMP-8.4, both nearly 100% accurate. No antigenic cross-reactivity was observed and reactivity index was similar to that for negative Chagas disease individuals.
Conclusions: Our results showed an outstanding performance of IBMP-8.1 and IBMP-8.4 chimeric antigens by ELISA and suggest both chimeric antigens could also be used for Chagas disease diagnosis in immigrants living in non-endemic settings.
Databáze: MEDLINE
Externí odkaz: